the staff of the Ridgewood blog
Ridgewood NJ, Eli Lilly, the pharmaceutical giant, launched a direct-to-consumer website yesterday, providing its customers with the option to obtain third-party prescriptions for its medications, including the newly approved weight loss injectable Zepbound (similar to Novo Nordisk’s Wegovy/Ozempic). Through the site, users can connect to a telehealth service, enabling them to quickly receive prescriptions before making a purchase.
Around 70% of Americans are either obese or overweight, conditions associated with increased health risks. The introduction of Zepbound signifies the progression in the utilization of GLP-1 agonists, which, like Zepbound, mimic a gut hormone to suppress hunger and enhance insulin production. Studies have indicated an average weight reduction of 15%, along with various other health benefits.
The demand for such treatments has strained supply chains and impacted industries significantly. This has led to strategic shifts from weight loss giant Weight Watchers and compelled food manufacturers to anticipate shifts in generational eating habits. Pfizer and Amgen are anticipated to seek approval for their versions this year in a market that analysts predict will reach $100 billion by 2035.
Take the Wall Street Walking Tour https://www.facebook.com/unofficialwallstreet #walkingtournyc, #nyc, #walkingtour, #manhattan, #newyorkcity, #nyctour, #nyctourism, #tournewyork, #tournyc, #tourismnyc, #newyork, #historicnyc, #travel, #bigapple, #wallstreet, #nychistory, #wallstreettours
